Orbimed Advisors LLC Vectiv Bio Holding Ag Transaction History

Orbimed Advisors LLC

$4.24 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	SELL	$7.34 - $9.15 $13.6 Million - $16.9 Million	-1,850,300 Reduced 26.41%	5,156,561 $43.9 Million
Q4 2022 Feb 14, 2023	BUY	$7.79 - $8.98 $4.15 Million - $4.79 Million	533,300 Added 8.24%	7,006,861 $60.7 Million
Q2 2022 Aug 15, 2022	BUY	$4.2 - $6.55 $4.8 Million - $7.49 Million	1,142,857 Added 21.44%	6,473,561 $35 Million
Q1 2022 May 16, 2022	BUY	$4.6 - $5.8 $491,739 - $620,020	106,900 Added 2.05%	5,330,704 $25.1 Million
Q4 2021 Feb 14, 2022	BUY	$2.83 - $7.26 $284,415 - $729,630	100,500 Added 1.96%	5,223,804 $25.6 Million
Q2 2021 Aug 16, 2021	BUY	$11.66 - $24.23 $59.7 Million - $124 Million	5,123,304 New	5,123,304 $59.7 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.